Market Intelligence

Access the latest earnings reports, market analysis, hot topics, and individual stock insights

Report Categories

View All

Recent Articles

View All
Nike NKE Q1 2026 Earnings Beat Revenue NA EPS 035 ArcBest ARCB Stock Analysis Climbs 230 Eyes on 12772 20260515 Bill Gates Discusses Trump Meeting Musks DOGE Initiative in Candid Interview Royal Observatory Warns Instant AI Answers Risk Trivialising Human Intelligence Implications for Tech Sector EU Trade Chief Bernd Lange Rejects US Pressure to FastTrack Deal Citing Democratic Process HealthStream HSTM Stalls at 2297 Consolidation Phase 20260514 Biologics ADMA Gains 165 Support Holds at 821 20260514 INVO Fertility IVF Stalls at 157 Consolidation Phase 20260514 Western WRN Q1 2026 Earnings Soft Quarter Raises Questions Socket Mobile Inc SCKT Holds Near Support After Slight Retreat FingerMotion FNGR Q4 2024 Earnings Slump EPS Falls Short of 001 Target SpaceX IPO Could Propel Elon Musk to Historic Trillionaire Status Goldman Sachs CD Offering at 4 Outpaces Average Bank Rates Telsey Advisory Group Highlights Lowes Resilience Amid Housing Market Challenges Bernstein Sees Up to 40 Upside Potential in Six Indian Pharma Stocks Taiwan Chip Stocks Rise Amid Nvidias 150 Billion Spending Announcement Barclays Posts 18 Profit Increase Raises FullYear Income Guidance BP Chairman Removed Amid Allegations of Bullying and Overbearing Conduct MKC Q1 2026 Earnings Strong EPS Beat Amid Market Challenges MG Q1 2026 Earnings EPS Beats Estimates by 553 as Company Reports Profitability Sunstone Hotel Investors Inc SHO Q1 2026 Earnings Strong EPS Surprise of 98 Outperforms Estimates Despite Stock Dip AEBI Q1 2026 Earnings EPS Falls Short of Estimates Despite Positive Stock Reaction CPHC Q2 2025 Earnings Narrow Loss and Modest Stock Gain Amid Quiet Quarter NI Holdings NODK Holds Steady Near Support as Insurance Sector Faces Mixed Signals Werewolf Therapeutics HOWL Stages a Modest Rebound Can the 044 Level Hold Fortune Brands Innovations FBIN Rallies 273 as Home Improvement Sentiment Improves CRISPR Therapeutics CRSP Edges Higher as GeneEditing Sector Regains Traction